Left Ventricular Assist Devices for Lifelong Support

Journal of the American College of Cardiology

Volumn 69, Issue 23, 2017, Pages 2845-2861

  Pinney, Sean P ^a   Anyanwu, Anelechi C ^a   Lala, Anuradha ^a   Teuteberg, Jeffrey J ^b   Uriel, Nir ^c   Mehra, Mandeep R ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

cardiothoracic surgery; heart failure; hemocompatibility

Indexed keywords

ANTICOAGULANT AGENT; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CLENBUTEROL; DIGOXIN; LISINOPRIL; LOSARTAN; OCTREOTIDE; SPIRONOLACTONE; THALIDOMIDE;

AORTIC REGURGITATION; ARTERIOVENOUS MALFORMATION; BIOCOMPATIBILITY; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CENTRAL VENOUS PRESSURE; CONTINUOUS FLOW LEFT VENTRICULAR ASSIST DEVICE; COST EFFECTIVENESS ANALYSIS; DEVICE INFECTION; DRUG WITHDRAWAL; FUNCTIONAL STATUS; HEART FAILURE; HEART RIGHT VENTRICLE FAILURE; HOSPITAL READMISSION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LEFT VENTRICULAR ASSIST DEVICE; MEDICAL DEVICE COMPLICATION; MINIMALLY INVASIVE SURGERY; MITRAL VALVE REGURGITATION; MORTALITY RATE; NONISCHEMIC CARDIOMYOPATHY; PATIENT SATISFACTION; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; PUMP DESIGN; PUMP THROMBOSIS; QUALITY OF LIFE; REVIEW; SHARED DECISION MAKING; STERNOTOMY; SURGICAL APPROACH; SURGICAL MORTALITY; THROMBOSIS; TRICUSPID VALVE REGURGITATION; VON WILLEBRAND DISEASE; COST BENEFIT ANALYSIS; ECONOMICS; HEART ASSIST DEVICE; PSYCHOLOGY;

COST-BENEFIT ANALYSIS; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; QUALITY OF LIFE;

EID: 85020257871     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.04.031     Document Type: Review

References (96)

1. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
2. Miller, L.W., Guglin, M., Patient selection for ventricular assist devices: a moving target. J Am Coll Cardiol 61 (2013), 1209–1221.
3. Rose, E.A., Gelijns, A.C., Moskowitz, A.J., et al., for the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 345 (2001), 1435–1443.
4. Rogers, J.G., Butler, J., Lansman, S.L., et al., for the InTrEPID Investigators. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. J Am Coll Cardiol 50 (2007), 741–747.
5. Slaughter, M.S., Rogers, J.G., Milano, C.A., et al., for the HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 361 (2009), 2241–2251.
6. Park, S.J., Milano, C.A., Rogers, J.G., et al., for the HeartMate II Clinical Investigators. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail 5 (2012), 241–248.
7. Jorde, U.P., Kushwaha, S.S., Tatooles, A.J., et al., for the HeartMate II Clinical Investigators. Results of the destination therapy post-Food and Drug Administration approval study with a continuous flow left ventricular assist device: a prospective study using the INTERMACS Registry (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol 63 (2014), 1751–1757.
8. Rogers, J.G., Pagani, F.D., Tatooles, A.J., et al. Intrapericardial left ventricular assist device for advanced heart failure. N Engl J Med 376 (2017), 451–460.
9. Estep, J.D., Starling, R.C., Horstmanshof, D.A., et al., for the ROADMAP Study Investigators. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: results from the ROADMAP study. J Am Coll Cardiol 66 (2015), 1747–1761.
10. Kirklin, J.K., Naftel, D.C., Pagani, F.D., et al. Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transplant 34 (2015), 1495–1504.
11. Mehra, M.R., Naka, Y., Uriel, N., et al., for the MOMENTUM 3 Investigators. A fully magnetically levitated circulatory pump for advanced heart failure. N Engl J Med 376 (2017), 440–450.
12. Mehra, M.R., The burden of haemocompatibility with left ventricular assist systems: a complex weave. Eur Heart J, 2017 Feb 23 [E-pub ahead of print].
13. Burkhoff, D., Sayer, G., Doshi, D., Uriel, N., Hemodynamics of mechanical circulatory support. J Am Coll Cardiol 66 (2015), 2663–2674.
14. Uriel, N., Sayer, G.T., Addetia, K., et al. Hemodynamic ramp tests in patients with left ventricular assist devices. J Am Coll Cardiol HF 4 (2016), 208–217.
15. Anyanwu, E., Patel, K., Henderson, C., et al. Normalization of hemodynamics following LVAD implantation may be related to improved long term outcome (abstr). J Card Fail, 21, 2015, S99.
16. Uriel, N., Morrison, K.A., Garan, A.R., et al. Development of a novel echocardiography ramp test for speed optimization and diagnosis of device thrombosis in continuous-flow left ventricular assist devices: the Columbia ramp study. J Am Coll Cardiol 60 (2012), 1764–1775.
17. Uriel, N., Levin, A.P., Sayer, G.T., et al. Left ventricular decompression during speed optimization ramps in patients supported by continuous-flow left ventricular assist devices: device-specific performance characteristics and impact on diagnostic algorithms. J Card Fail 21 (2015), 785–791.
18. Kirklin, J.K., Naftel, D.C., Kormos, R.L., et al. Fifth INTERMACS annual report: risk factor analysis from more than 6,000 mechanical circulatory support patients. J Heart Lung Transplant 32 (2013), 141–156.
19. Smedira, N.G., Hoercher, K.J., Lima, B., et al. Unplanned hospital readmissions after HeartMate II implantation: frequency, risk factors, and impact on resource use and survival. J Am Coll Cardiol HF 1 (2013), 31–39.
20. Teuteberg, J.J., Slaughter, M.S., Rogers, J.G., et al., for the ADVANCE Trial Investigators. The HVAD left ventricular assist device: risk factors for neurological events and risk mitigation strategies. J Am Coll Cardiol HF 3 (2015), 818–828.
21. Starling, R.C., Moazami, N., Silvestry, S.C., et al. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med 370 (2014), 33–40.
22. Kirklin, J.K., Naftel, D.C., Kormos, R.L., et al. Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device [published correction appears in J Heart Lung Transplant 2015;34:1356]. J Heart Lung Transplant 33 (2014), 12–22.
23. Lampert, B.C., Teuteberg, J.J., Right ventricular failure after left ventricular assist devices. J Heart Lung Transplant 34 (2015), 1123–1130.
24. Kapelios, C.J., Charitos, C., Kaldara, E., et al. Late-onset right ventricular dysfunction after mechanical support by a continuous-flow left ventricular assist device. J Heart Lung Transplant 34 (2015), 1604–1610.
25. Fitzpatrick, J.F. 3rd, Frederick, J.R., Hsu, V.M., et al. Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support. J Heart Lung Transplant 27 (2008), 1286–1292.
26. Kormos, R.L., Teuteberg, J.J., Pagani, F.D., et al., for the HeartMate II Clinical Investigators. Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. J Thorac Cardiovasc Surg 139 (2010), 1316–1324.
27. Kang, G., Ha, R., Banerjee, D., Pulmonary artery pulsatility index predicts right ventricular failure after left ventricular assist device implantation. J Heart Lung Transplant 35 (2016), 67–73.
28. Vivo, R.P., Cordero-Reyes, A.M., Qamar, U., et al. Increased right-to-left ventricle diameter ratio is a strong predictor of right ventricular failure after left ventricular assist device. J Heart Lung Transplant 32 (2013), 792–799.
29. Grant, A.D., Smedira, N.G., Starling, R.C., Marwick, T.H., Independent and incremental role of quantitative right ventricular evaluation for the prediction of right ventricular failure after left ventricular assist device implantation. J Am Coll Cardiol 60 (2012), 521–528.
30. Goda, M., Jacobs, S., Rega, F., et al. Time course of acquired von Willebrand disease associated with two types of continuous-flow left ventricular assist devices: HeartMate II and CircuLite Synergy Pocket Micro-pump. J Heart Lung Transplant 32 (2013), 539–545.
31. Joyce, D., Crow, S., Li, Z., et al. Pilot investigation of a novel testing strategy for bleeding in ventricular assist device recipients. J Heart Lung Transplant 31 (2012), 750–756.
32. Suarez, J., Patel, C.B., Felker, G.M., Becker, R., Hernandez, A.F., Rogers, J.G., Mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices. Circ Heart Failure 4 (2011), 779–784.
33. Feldman, D., Pamboukian, S.V., Teuteberg, J.J., et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant 32 (2013), 157–187.
34. Loyaga-Rendon, R.Y., Hashim, T., Tallaj, J.A., et al. Octreotide in the management of recurrent gastrointestinal bleed in patients supported by continuous flow left ventricular assist devices. ASAIO J 61 (2015), 107–109.
35. Draper, K., Kale, P., Martin, B., Cordero, K., Ha, R., Banerjee, D., Thalidomide for treatment of gastrointestinal angiodysplasia in patients with left ventricular assist devices: case series and treatment protocol. J Heart Lung Transplant 34 (2014), 132–134.
36. Koval, C.E., Thuita, L., Moazami, N., Blackstone, E., Evolution and impact of drive-line infection in a large cohort of continuous flow ventricular assist device recipients. J Heart Lung Transplant 33 (2014), 1164–1172.
37. Goldstein, D.J., Naftel, D., Holman, W., et al. Continuous-flow devices and percutaneous site infections: clinical outcomes. J Heart Lung Transplant 31 (2012), 1151–1157.
38. John, R., Aaronson, K.D., Pae, W.E., et al., for the HeartWare Bridge to Transplant ADVANCE Trial Investigators. Drive-line infections and sepsis in patients receiving the HVAD system as a left ventricular assist device. J Heart Lung Transplant 33 (2014), 1066–1073.
39. Toda, K., Yonemoto, Y., Fujita, T., et al. Risk analysis of bloodstream infection during long-term left ventricular assist device support. Ann Thorac Surg 94 (2012), 1387–1393.
40. Stulak, J.M., Deo, S., Schirger, J., et al. Preoperative atrial fibrillation increases risk of thromboembolic events after left ventricular assist device implantation. Ann Thorac Surg 96 (2013), 2161–2167.
41. Boyle, A.J., Jorde, U.P., Sun, B., et al., for the HeartMate II Clinical Investigators. Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients. J Am Coll Cardiol 63 (2014), 880–888.
42. Cowger, J.A., Romano, M.A., Shah, P., et al. Hemolysis: a harbinger of adverse outcome after left ventricular assist device implant. J Heart Lung Transplant 33 (2014), 35–43.
43. Trachtenberg, B.H., Cordero-Reyes, A.M., Aldeiri, M., et al. Persistent blood stream infection in patients supported with a continuous-flow left ventricular assist device is associated with an increased risk of cerebrovascular accidents. J Card Fail 21 (2015), 119–125.
44. Stulak, J.M., Lee, D., Haft, J.W., et al. Gastrointestinal bleeding and subsequent risk of thromboembolic events during support with a left ventricular assist device. J Heart Lung Transplant 33 (2014), 60–64.
45. Lampert, B.C., Eckert, C., Weaver, S., et al. Blood pressure control in continuous flow left ventricular assist devices: efficacy and impact on adverse events. Ann Thorac Surg 97 (2014), 139–146.
46. Nassif, M.E., Tibrewala, A., Raymer, D.S., et al. Systolic blood pressure on discharge after left ventricular assist device insertion is associated with subsequent stroke. J Heart Lung Transplant 34 (2015), 503–508.
47. Najjar, S.S., Slaughter, M.S., Pagani, F.D., et al., for the HVAD Bridge to Transplant ADVANCE Trial Investigators. An analysis of pump thrombus events in patients in the HeartWare ADVANCE bridge to transplant and continued access protocol trial. J Heart Lung Transplant 33 (2014), 23–34.
48. Kirklin, J.K., Naftel, D.C., Pagani, F.D., et al. Pump thrombosis in the Thoratec HeartMate II device: an update analysis of the INTERMACS registry. J Heart Lung Transplant 34 (2015), 1515–1526.
49. Smedira, N.G., Blackstone, E.H., Ehrlinger, J., et al. Current risks of HeartMate II pump thrombosis: non-parametric analysis of Interagency Registry for Mechanically Assisted Circulatory Support data. J Heart Lung Transplant 34 (2015), 1527–1534.
50. Mehra, M.R., Stewart, G.C., Uber, P.A., The vexing problem of thrombosis in long-term mechanical circulatory support. J Heart Lung Transplant 33 (2014), 1–11.
51. Maltais, S., Kilic, A., Nathan, S., et al., for the PREVENT Study Investigators. PREVENtion of HeartMate II pump Thrombosis through clinical management: the PREVENT multi-center study. J Heart Lung Transplant 36 (2017), 1–12.
52. Holman, W.A., Teitel, E.R., Itescu, S., Biologic barriers to mechanical circulatory support. Frazier, O.H., Kirklin, J.K., (eds.) Mechanical Circulatory Support, Volume 1, 2006, Elsevier, Philadelphia, PA, 9–32.
53. Dimasi, A., Rasponi, M., Sheriff, J., et al. Microfluidic emulation of mechanical circulatory support device shear-mediated platelet activation. Biomed Microdevices, 17, 2015, 117.
54. Muthiah, K., Robson, D., Macdonald, P.S., et al. Increased incidence of angiodysplasia of the gastrointestinal tract and bleeding in patients with continuous flow left ventricular assist devices (LVADs). Int J Artif Organs 36 (2013), 449–454.
55. Lee, M., Akashi, H., Kato, T.S., et al. Vascular inflammation and abnormal aortic histomorphometry in patients after pulsatile-and continuous-flow left ventricular assist device placement. J Heart Lung Transplant 35 (2016), 1085–1091.
56. Moazami, N., Dembitsky, W.P., Adamson, R., et al. Does pulsatility matter in the era of continuous-flow blood pumps?. J Heart Lung Transplant 34 (2015), 999–1004.
57. Susen, S., Rauch, A., Van Belle, E., Vincentelli, A., Lenting, P.J., Circulatory support devices: fundamental aspects and clinical management of bleeding and thrombosis. J Thromb Haemost 13 (2015), 1757–1767.
58. Heatley, G., Sood, P., Goldstein, D., et al., for the MOMENTUM 3 Investigators. Clinical trial design and rationale of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) investigational device exemption clinical study protocol. J Heart Lung Transplant 35 (2016), 528–536.
59. Netuka, I., Sood, P., Pya, Y., et al. Fully magnetically levitated left ventricular assist system for treating advanced HF: a multicenter study. J Am Coll Cardiol 66 (2015), 2579–2589.
60. Netuka, I., Kvasnička, T., Kvasnička, J., et al. Evaluation of von Willebrand factor with a fully magnetically levitated centrifugal continuous-flow left ventricular assist device in advanced heart failure. J Heart Lung Transplant 35 (2016), 860–867.
61. Meyer, A.L., Malehsa, D., Budde, U., Bara, C., Haverich, A., Strueber, M., Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device. J Am Coll Cardiol HF 2 (2014), 141–145.
62. Anyanwu, A.C., Itagaki, S., Pinney, S., Adams, D.H., Initial experience with routine less invasive implantation of HeartMate II left ventricular assist device without median sternotomy. Eur J Cardiothorac Surg 46 (2014), 985–990.
63. Sileshi, B., Haglund, N.A., Davis, M.E., et al. In-hospital outcomes of a minimally invasive off-pump left thoracotomy approach using a centrifugal continuous-flow left ventricular assist device. J Heart Lung Transplant 34 (2015), 107–112.
64. Reineke, D.C., Carrel, T.P., Less invasive left ventricular assist device implantation: a match changer!. J Thorac Dis 7 (2015), 783–786.
65. Cowger, J., Rao, V., Massey, T., et al. Comprehensive review and suggested strategies for the detection and management of aortic insufficiency in patients with a continuous-flow left ventricular assist device. J Heart Lung Transplant 34 (2015), 149–157.
66. Krishan, K., Nair, A., Pinney, S., Adams, D.H., Anyanwu, A.C., Liberal use of tricuspid-valve annuloplasty during left-ventricular assist device implantation. Eur J Cardiothorac Surg 41 (2012), 213–217.
67. Brewer, R.J., Cabrera, R., El-Atrache, M., et al. Relationship of tricuspid repair at the time of left ventricular assist device implantation and survival. Int J Artif Organs 37 (2014), 834–838.
68. Adamson, R.M., Stahovich, M., Chillcott, S., et al. Clinical strategies and outcomes in advanced heart failure patients older than 70 years of age receiving the HeartMate II left ventricular assist device: a community hospital experience. J Am Coll Cardiol 57 (2011), 2487–2495.
69. Taghavi, S., Hamad, E., Wilson, L., et al. Mitral valve repair at the time of continuous-flow left ventricular assist device implantation confers meaningful decrement in pulmonary vascular resistance. ASAIO J 59 (2013), 469–473.
70. Patel, M., Rojas, F., Shabari, F.R., et al. Safety and feasibility of open chest epicardial mapping and ablation of ventricular tachycardia during the period of left ventricular assist device implantation. J Cardiovasc Electrophysiol 27 (2016), 95–101.
71. Ascheim, D.D., Gelijns, A.C., Goldstein, D., et al. Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices. Circulation 129 (2014), 2287–2296.
72. Hall, J.L., Fermin, D.R., Birks, E.J., et al. Clinical, molecular, and genomic changes in response to a left ventricular assist device. J Am Coll Cardiol 57 (2011), 641–652.
73. Frazier, O.H., Myers, T.J., Left ventricular assist system as a bridge to myocardial recovery. Ann Thorac Surg 68 (1999), 734–741.
74. Birks, E.J., Tansley, P.D., Hardy, J., et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 355 (2006), 1873–1884.
75. Aaronson, K.D., Pagani, F.D., Maybaum, S.W., et al. 3 Combination therapy with pulsatile left ventricular assist device, heart failure medication and clenbuterol in chronic heart failure: results from HARPS. J Heart Lung Transpl 30 (2011), S8–S9 (abstr).
76. Birks, E.J., George, R.S., Hedger, M., et al. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation 123 (2011), 381–390.
77. Formica, P., Murthy, S., Edwards, P., Goldstein, D., Maybaum, S., A structured 3-step approach to evaluate cardiac recovery with continuous flow circulatory support. J Heart Lung Transplant 29 (2010), 1440–1442.
78. Patel, S.R., Saeed, O., Murthy, S., et al. Combining neurohormonal blockade with continuous-flow left ventricular assist device support for myocardial recovery: a single-arm prospective study. J Heart Lung Transplant 32 (2013), 305–312.
79. Birks, E.J., Drakos, S.G., Selzman, C.H., et al. Remission from Stage D Heart Failure (RESTAGE-HF): early results from a prospective multi-center study of myocardial recovery (abstr). J Heart Lung Transplant 34 (2015), S40–S41.
80. Mann, D.L., Barger, P.M., Burkhoff, D., Myocardial recovery and the failing heart: myth, magic, or molecular target?. J Am Coll Cardiol 60 (2012), 2465–2472.
81. Drakos, S.G., Wever-Pinzon, O., Selzman, C.H., et al., for the UCAR (Utah Cardiac Recovery Program) Investigators. Magnitude and time course of changes induced by continuous-flow left ventricular assist device unloading in chronic heart failure: insights into cardiac recovery. J Am Coll Cardiol 61 (2013), 1985–1994.
82. Gupta, D.K., Skali, H., Rivero, J., et al. Assessment of myocardial viability and left ventricular function in patients supported by a left ventricular assist device. J Heart Lung Transplant 33 (2014), 372–381.
83. Razeghi, P., Sharma, S., Ying, J., et al. Atrophic remodeling of the heart in vivo simultaneously activates pathways of protein synthesis and degradation. Circulation 108 (2003), 2536–2541.
84. Yacoub, M.H., A novel strategy to maximize the efficacy of left ventricular assist devices as a bridge to recovery. Eur Heart J 22 (2001), 534–540.
85. Diakos, N.A., Selzman, C.H., Sachse, F.B., et al. Myocardial atrophy and chronic mechanical unloading of the failing human heart: implications for cardiac assist device-induced myocardial recovery. J Am Coll Cardiol 64 (2014), 1602–1612.
86. Klotz, S., Foronjy, R.F., Dickstein, M.L., et al. Mechanical unloading during left ventricular assist device support increases left ventricular collagen cross-linking and myocardial stiffness. Circulation 112 (2005), 364–374.
87. Drakos, S.G., Mehra, M.R., Clinical myocardial recovery during long-term mechanical support in advanced heart failure: insights into moving the field forward. J Heart Lung Transplant 35 (2016), 413–420.
88. Allen, L.A., Stevenson, L.W., Grady, K.L., et al. Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation 125 (2012), 1928–1952.
89. Colorado Program for Patient-Centered Decisions. Decision aids. Available at: https://patientdecisionaid.org/. Accessed April 20, 2017.
90. Kirklin, J.K., Naftel, D.C., Pagani, F.D., et al. Long-term mechanical circulatory support (destination therapy): on track to compete with heart transplantation?. J Thorac Cardiovasc Surg 144 (2012), 584–603.
91. Stehlik, J., Estep, J.D., Selzman, C.H., et al., for the ROADMAP Study Investigators. Patient reported quality of life with mechanical circulatory support vs continued medical therapy in ambulatory heart failure patients (abstr). J Heart Lung Transplant, 35, 2016, S26.
92. Dunlay, S.M., Park, S.J., Joyce, L.D., et al. Frailty and outcomes after implantation of left ventricular assist device as destination therapy. J Heart Lung Transplant 33 (2014), 359–365.
93. Thomas Jefferson University. Frailty: Prevalence and Response to Left Ventricular Assist Device Therapy in Older Heart Failure Patients. National Library of Medicine. 2015. Available at: https://clinicaltrials.gov/ct2/show/NCT02156583. Accessed April 13, 2017.
94. Cubanski J, Neuman T. The Facts on Medicare Spending and Financing. Kaiser Family Foundation. 2016. Available at: http://kff.org/medicare/issue-brief/the-facts-on-medicare-spending-and-financing/. Accessed April 13, 2017.
95. Shreibati, J.B., Goldhaber-Fiebert, J.D., Banerjee, D., Owens, D.K., Hlatky, M.A., Cost-effectiveness of left ventricular assist devices in ambulatory patients with advanced heart failure. J Am Coll Cardiol HF 5 (2017), 110–119.
96. Rogers, J.G., Bostic, R.R., Tong, K.B., Adamson, R., Russo, M., Slaughter, M.S., Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy. Circ Heart Fail 5 (2012), 10–16.